Alvotech Announces Two Successful Adalimumab Studies

AVT02 Humira Rival Has Higher Concentration Of 100mg/ml

 
• By Akriti Seth

Alvotech’s AVT02 proposed adalimumab biosimilar has seen positive results from two clinical trials. The high concentration dosage form of AVT02 differentes it from most of its biosimilar competitors.

Clinical_Trial_Globe
Alvotech’s AVT02 clinical trials successfully demonstrated pharmacokinetics similarity and equivalent efficacy • Source: Shutterstock

More from Biosimilars

More from Products